BioventusBVS
About: Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Employees: 1,030
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
95% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 20
50% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 20
40% more capital invested
Capital invested by funds: $180M [Q1] → $253M (+$72.3M) [Q2]
23% more funds holding
Funds holding: 83 [Q1] → 102 (+19) [Q2]
14.12% more ownership
Funds ownership: 54.7% [Q1] → 68.82% (+14.12%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
31% less call options, than puts
Call options by funds: $877K | Put options by funds: $1.28M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Craig-Hallum Alexander Nowak 67% 1-year accuracy 8 / 12 met price target | 35%upside $17 | Buy Maintained | 27 Sept 2024 |
Canaccord Genuity William Plovanic 52% 1-year accuracy 11 / 21 met price target | 4%downside $12 | Buy Maintained | 13 Aug 2024 |
Craig-Hallum Alexander Nowak 67% 1-year accuracy 8 / 12 met price target | 4%downside $12 | Buy Maintained | 7 Aug 2024 |